PCA
FATE icon

Personal Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Personal Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,011
Closed -$240K – 464
2020
Q3 		$240K Buy
+6,011
New +$210K ﹤0.01% 370

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Personal Capital Advisors's FATE Position: Q4 2020 in Review

Personal Capital Advisors sold out of Fate Therapeutics (FATE) in Q4 2020, closing a stake of 6,011 shares — an estimated $240K sold.

Personal Capital Advisors first reported a position in FATE in Q3 2020 and held it in 1 quarter. The position peaked at $240K in Q3 2020. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • Personal Capital Advisors reported no remaining Fate Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Personal Capital Advisors sold 6,011 Fate Therapeutics shares in Q4 2020, an estimated $240K.
  • Personal Capital Advisors first reported a position in Fate Therapeutics in Q3 2020 and held it in 1 quarter.
  • Personal Capital Advisors's Fate Therapeutics position peaked at $240K in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Personal Capital Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.